Association of AFP with Hepatocellular Carcinoma Subtypes

Background/Objectives: Alpha-fetoprotein (AFP) is often elevated in hepatocellular carcinoma (HCC) and has been linked to poor prognosis. Among HCC subtypes, the association is less defined. We aimed to characterize AFP and their association with prognosis for the fibrolamellar, scirrhous, clear-cell, spindle-cell, and pleomorphic subtypes of HCC. Methods: Patients in the National Cancer Database (NCDB) diagnosed with HCC between 1998–2021, including not otherwise specified (NOS), fibrolamellar, scirrhous, clear-cell, spindle-cell, and pleomorphic were included. Elevated AFP was defined as 400 ng/mL or above. Associations between clinical characteristics, including AFP levels, and HCC subtypes were analyzed using two-sample t-test, chi-square, and Fisher exact tests. Survival was assessed using Kaplan–Meier curves with log-rank tests. Results: The study population included 168,470 patients, of which 166,778 (99.0%) were HCC NOS, followed by 872 (0.5%) clear-cell, 417 (0.2%) fibrolamellar, 251 (0.2%) scirrhous, 136 (0.1%) spindle-cell, and 16 (0.01%) pleomorphic. Elevated AFP was highest in the spindle-cell subtype (30.9%), followed by HCC NOS (29.4%), scirrhous (25.1%), clear-cell (23.4%), and fibrolamellar (15.6%) (p < 0.0001). Elevated AFP was significantly different across stage of disease with elevation in 11.9% of fibrolamellar, 6.8% of scirrhous, 35.7% of spindle-cell, 25.2% of clear-cell, and 17.6% of HCC NOS at stage 2; 22.5%, 50%, 33.3%, 28.2%, and 44.2%, respectively at stage 3; and 13.8%, 30.4%, 31.7%, 42.2%, and 53.2%, respectively, at stage 4 (all p < 0.005). Elevated AFP was associated with decreased survival for the fibrolamellar (9.7 months when elevated vs. 39 months when not elevated), scirrhous (3.8 vs. 24.2) and clear-cell (7.2 vs. 25.9) subtypes (p < 0.0001). Conclusions: Elevated AFP is least prevalent for fibrolamellar HCC, including when stratifying by disease stage, though it is associated with worse survival in that population. AFP elevation may offer important prognostic information when rare subtypes are diagnosed.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-02
DOI
https://doi.org/10.3390/cancers18213524
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association of AFP with Hepatocellular Carcinoma Subtypes

Linda T. Qu, Callie Rose, Ling Wang, James Hosner et al.
Cancers
Hepatocellular Carcinoma Treatment and Prognosis
article

Association of AFP with Hepatocellular Carcinoma Subtypes

Linda T. Qu, Callie Rose, Ling Wang, James Hosner, Seung Hwan Chung
article en

Abstract

Background/Objectives: Alpha-fetoprotein (AFP) is often elevated in hepatocellular carcinoma (HCC) and has been linked to poor prognosis. Among HCC subtypes, the association is less defined. We aimed to characterize AFP and their association with prognosis for the fibrolamellar, scirrhous, clear-cell, spindle-cell, and pleomorphic subtypes of HCC. Methods: Patients in the National Cancer Database (NCDB) diagnosed with HCC between 1998–2021, including not otherwise specified (NOS), fibrolamellar, scirrhous, clear-cell, spindle-cell, and pleomorphic were included. Elevated AFP was defined as 400 ng/mL or above. Associations between clinical characteristics, including AFP levels, and HCC subtypes were analyzed using two-sample t-test, chi-square, and Fisher exact tests. Survival was assessed using Kaplan–Meier curves with log-rank tests. Results: The study population included 168,470 patients, of which 166,778 (99.0%) were HCC NOS, followed by 872 (0.5%) clear-cell, 417 (0.2%) fibrolamellar, 251 (0.2%) scirrhous, 136 (0.1%) spindle-cell, and 16 (0.01%) pleomorphic. Elevated AFP was highest in the spindle-cell subtype (30.9%), followed by HCC NOS (29.4%), scirrhous (25.1%), clear-cell (23.4%), and fibrolamellar (15.6%) (p < 0.0001). Elevated AFP was significantly different across stage of disease with elevation in 11.9% of fibrolamellar, 6.8% of scirrhous, 35.7% of spindle-cell, 25.2% of clear-cell, and 17.6% of HCC NOS at stage 2; 22.5%, 50%, 33.3%, 28.2%, and 44.2%, respectively at stage 3; and 13.8%, 30.4%, 31.7%, 42.2%, and 53.2%, respectively, at stage 4 (all p < 0.005). Elevated AFP was associated with decreased survival for the fibrolamellar (9.7 months when elevated vs. 39 months when not elevated), scirrhous (3.8 vs. 24.2) and clear-cell (7.2 vs. 25.9) subtypes (p < 0.0001). Conclusions: Elevated AFP is least prevalent for fibrolamellar HCC, including when stratifying by disease stage, though it is associated with worse survival in that population. AFP elevation may offer important prognostic information when rare subtypes are diagnosed.

CancersVol. 18(21)
Michigan State University (US)
Openalex Percentile: Top 15%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon